Publications

Nature communications

Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.

17-06-2026

ESMO real world data and digital oncology

Validating large language model-assisted data extraction from clinical notes.

01-06-2026

European journal of cancer (Oxford, England : 1990)

From prediction to precision: Biomarker discovery and predictive modeling for personalized immune checkpoint blockade therapy.

15-05-2026

NPJ breast cancer

Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring.

06-05-2026

FEBS letters

Genetic interactions, synthetic lethality and complexity in cancer vulnerability mapping-Insights and perspectives from the 2nd EuroDepMap symposium.

01-04-2026

Cancer research

C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3.

16-03-2026

Molecular & cellular proteomics : MCP

Cell-State-Specific Drug Responses are Associated With Differences in Signaling Network Wiring.

01-03-2026

Cancer discovery

Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy.

12-01-2026

Bioinformatics (Oxford, England)

Reconstructing and comparing signal transduction networks from single-cell protein quantification data.

02-01-2026

Cell reports. Medicine

CfDNA-based copy-number dynamics during anti-PD1 treatment in metastatic triple negative breast cancer.

16-12-2025

Nature

Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.

01-12-2025

Lung cancer (Amsterdam, Netherlands)

Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma.

01-11-2025

European journal of cancer (Oxford, England : 1990)

Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trial.

16-10-2025

Clinical cancer research : an official journal of the American Association for Cancer Research

Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study.

15-09-2025

Cancer research

The C-Terminal Kinase Domain-Binding and Suppression Motif Prevents Constitutive Activation of FGFR2.

02-09-2025

Nature

NASP modulates histone turnover to drive PARP inhibitor resistance.

01-09-2025

Cell reports. Medicine

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.

15-07-2025

Science (New York, N.Y.)

Zincore, an atypical coregulator, binds zinc finger transcription factors to control gene expression.

03-07-2025

Nature genetics

The synthetic lethal interaction between CDS1 and CDS2 is a vulnerability in uveal melanoma and across multiple tumor types.

01-07-2025

Cancer immunology, immunotherapy : CII

Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures.

25-06-2025

Genome biology

Endometrial tumorigenesis involves epigenetic plasticity demarcating non-coding somatic mutations and 3D-genome alterations.

09-05-2025

Nature communications

Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial.

14-04-2025

Genome medicine

Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications.

20-03-2025

NPJ breast cancer

Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality.

23-01-2025

Nature medicine

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

01-11-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.

01-10-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment.

13-09-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.

03-09-2024

ESMO real world data and digital oncology

Clinical text mining of the performance status and progression-free survival to facilitate data collection in cancer research: an exploratory study.

01-09-2024

Cell reports. Medicine

A pan-cancer screen identifies drug combination benefit in cancer cell lines at the individual and population level.

20-08-2024

iScience

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.

16-08-2024

The Journal of pathology

Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts.

01-07-2024

The New England journal of medicine

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

06-06-2024

Science (New York, N.Y.)

DNA damage induces p53-independent apoptosis through ribosome stalling.

17-05-2024

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Evaluating the effectiveness of pre-operative diagnosis of ovarian cancer using minimally invasive liquid biopsies by combining serum human epididymis protein 4 and cell-free DNA in patients with an ovarian mass.

06-05-2024

Cell

A pan-cancer analysis of the microbiome in metastatic cancer.

25-04-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.

01-04-2024

Nature communications

Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.

21-03-2024

Cancer cell

Distinct spatiotemporal dynamics of CD8⁺ T cell-derived cytokines in the tumor microenvironment.

08-01-2024

The Journal of experimental medicine

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.

06-11-2023

Clinical cancer research : an official journal of the American Association for Cancer Research

Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features.

15-09-2023

British journal of cancer

Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights.

01-09-2023

European urology

Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17].

01-06-2023

Cell reports

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.

30-05-2023

Cancer cell

A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.

08-05-2023

BMC bioinformatics

ecpc: an R-package for generic co-data models for high-dimensional prediction.

26-04-2023

European urology

Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.

01-04-2023

British journal of cancer

Tumour-educated platelets for breast cancer detection: biological and technical insights.

01-04-2023

Nature cancer

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

01-04-2023

Nature medicine

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.

01-03-2023

Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial.

Validating large language model-assisted data extraction from clinical notes.

From prediction to precision: Biomarker discovery and predictive modeling for personalized immune checkpoint blockade therapy.

Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring.

Genetic interactions, synthetic lethality and complexity in cancer vulnerability mapping-Insights and perspectives from the 2nd EuroDepMap symposium.

C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3.

Cell-State-Specific Drug Responses are Associated With Differences in Signaling Network Wiring.

Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy.

Reconstructing and comparing signal transduction networks from single-cell protein quantification data.

CfDNA-based copy-number dynamics during anti-PD1 treatment in metastatic triple negative breast cancer.

Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.

Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma.

Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trial.

Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study.

The C-Terminal Kinase Domain-Binding and Suppression Motif Prevents Constitutive Activation of FGFR2.

NASP modulates histone turnover to drive PARP inhibitor resistance.

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.

Zincore, an atypical coregulator, binds zinc finger transcription factors to control gene expression.

The synthetic lethal interaction between CDS1 and CDS2 is a vulnerability in uveal melanoma and across multiple tumor types.

Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures.

Endometrial tumorigenesis involves epigenetic plasticity demarcating non-coding somatic mutations and 3D-genome alterations.

Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial.

Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications.

Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality.

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.

Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment.

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.

Clinical text mining of the performance status and progression-free survival to facilitate data collection in cancer research: an exploratory study.

A pan-cancer screen identifies drug combination benefit in cancer cell lines at the individual and population level.

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.

Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts.

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

DNA damage induces p53-independent apoptosis through ribosome stalling.

Evaluating the effectiveness of pre-operative diagnosis of ovarian cancer using minimally invasive liquid biopsies by combining serum human epididymis protein 4 and cell-free DNA in patients with an ovarian mass.

A pan-cancer analysis of the microbiome in metastatic cancer.

Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.

Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.

Distinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment.

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.

Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features.

Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights.

Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17].

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.

A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.

ecpc: an R-package for generic co-data models for high-dimensional prediction.

Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer.

Tumour-educated platelets for breast cancer detection: biological and technical insights.

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.

This site uses cookies

Distinct spatiotemporal dynamics of CD8⁺ T cell-derived cytokines in the tumor microenvironment.